MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-12-2025
XOMA Corporation Market Cap 2011-2025 | XOMA
As of December 12, 2025 XOMA Corporation has a market cap of $ 304 K
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap XOMA Corporation
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 282 K | 253 K | 248 M | 387 M | 204 M | 101 M | 254 M | 25.3 M | 119 M | 382 M | 693 M | 167 M | 43.9 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 693 M | 253 K | 202 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AbbVie
ABBV
|
342 B | $ 223.01 | -0.99 % | $ 395 B |  USA |
 |
ARCA biopharma
ABIO
|
484 M | - | 1052.0 % | $ 415 M | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
445 M | $ 4.68 | 1.85 % | $ 777 M |  Canada |
 |
Aclaris Therapeutics
ACRS
|
152 M | $ 3.38 | 3.21 % | $ 261 M | USA |
 |
Acasti Pharma
ACST
|
40.7 M | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
2.05 B | - | -15.15 % | $ 60.3 M |  Britain |
 |
Aeglea BioTherapeutics
AGLE
|
724 M | - | - | $ 1.01 B | USA |
 |
Ascendis Pharma A/S
ASND
|
7.37 B | $ 212.3 | 5.5 % | $ 5 B |  Danmark |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
33.6 B | - | - | $ 40.3 B | USA |
 |
BioVie
BIVI
|
2.44 M | $ 1.54 | -2.53 % | $ 2.28 M | USA |
 |
Albireo Pharma
ALBO
|
538 M | - | -0.23 % | $ 916 M | USA |
 |
Aptorum Group Limited
APM
|
4.09 M | $ 1.33 | -1.48 % | $ 7.25 M |  China |
 |
Alpine Immune Sciences
ALPN
|
269 M | - | - | $ 2.17 B | USA |
 |
Alterity Therapeutics Limited
ATHE
|
895 M | $ 3.4 | 1.49 % | $ 8.18 B |  Australia |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
28.9 M | - | -1.52 % | $ 24.7 M | USA |
 |
AstraZeneca PLC
AZN
|
81.2 B | $ 90.34 | -1.28 % | $ 96.9 B | Britain |
 |
Amphastar Pharmaceuticals
AMPH
|
1.31 B | $ 25.76 | 0.19 % | $ 1.25 B | USA |
 |
Anika Therapeutics
ANIK
|
373 M | $ 9.53 | -1.19 % | $ 140 M | USA |
 |
Aytu BioScience
AYTU
|
15.8 M | $ 2.33 | 2.3 % | $ 14.6 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
5.65 B | - | -6.81 % | $ 3.04 B | USA |
 |
Avenue Therapeutics
ATXI
|
544 K | - | -52.27 % | $ 4.45 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
2.83 B | - | - | - |  Russia |
 |
Axon Enterprise
AXON
|
39.8 B | $ 586.28 | 3.15 % | $ 44.4 B | USA |
 |
Biogen
BIIB
|
19.3 B | $ 173.03 | -2.55 % | $ 25.2 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
3.16 B | $ 0.29 | -5.01 % | $ 631 M |  Israel |
 |
Brickell Biotech
BBI
|
11.4 M | - | -5.38 % | $ 6.06 M | USA |
 |
Benitec Biopharma
BNTC
|
556 M | $ 12.91 | 0.78 % | $ 531 M | USA |
 |
BioNTech SE
BNTX
|
62.9 B | $ 95.9 | 0.17 % | $ 27.2 B |  Germany |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
8.59 B | $ 11.55 | 8.86 % | $ 747 M | USA |
 |
Enochian Biosciences
ENOB
|
116 M | - | - | $ 40.5 M | USA |
 |
Catalyst Biosciences
CBIO
|
33.6 M | $ 15.32 | 5.73 % | $ 1.01 B | USA |
 |
Acer Therapeutics
ACER
|
12.1 M | - | 2.71 % | $ 14 M | USA |
 |
BeiGene, Ltd.
BGNE
|
253 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Cerus Corporation
CERS
|
301 M | $ 2.14 | 13.23 % | $ 395 M | USA |
 |
Acorda Therapeutics
ACOR
|
16.7 M | - | -24.86 % | $ 820 K | USA |
 |
Applied Molecular Transport
AMTI
|
22.1 M | - | - | $ 10.1 M | USA |
 |
Burford Capital Limited
BUR
|
2.09 B | $ 9.15 | -0.44 % | $ 1.47 B | Britain |
 |
Berkeley Lights
BLI
|
117 M | - | -7.31 % | $ 87 M | USA |
 |
bluebird bio
BLUE
|
67 M | - | - | $ 546 M | USA |
 |
Cellectar Biosciences
CLRB
|
44.5 M | $ 3.81 | -5.35 % | $ 46.6 M | USA |
 |
Bristol-Myers Squibb Company
BMY
|
114 B | $ 51.05 | -0.32 % | $ 103 B | USA |
 |
Abeona Therapeutics
ABEO
|
149 M | $ 5.5 | 0.46 % | $ 118 M | USA |
 |
ADiTx Therapeutics
ADTX
|
59.2 K | $ 2.36 | -7.29 % | $ 31.1 K | USA |
 |
BioXcel Therapeutics
BTAI
|
5.37 M | $ 2.1 | -4.34 % | $ 5.32 M | USA |
 |
Coherus BioSciences
CHRS
|
209 M | $ 1.42 | 6.77 % | $ 134 M | USA |
 |
BioLineRx Ltd.
BLRX
|
1.35 B | $ 3.22 | -2.72 % | $ 908 M | Israel |
 |
Celldex Therapeutics
CLDX
|
1.31 M | $ 28.33 | 0.5 % | $ 1.82 M | USA |
 |
Advaxis
ADXS
|
1.87 M | - | -9.65 % | $ 45.9 M | USA |
 |
Baudax Bio
BXRX
|
779 K | - | 0.59 % | $ 63 K | USA |
 |
Завод ДИОД
DIOD
|
661 M | - | - | - | Russia |